Dr. Chari reports results from a trial of daratumumab plus carfilzomib-dexamethasone in patients with lenalidomide-refractory disease.
Skip Nav Destination
Evaluating New Myeloma Agent Combinations in Lenalidomide-Refractory Patients
December 30, 2021
Content License:Private